Why GLP-1 Telehealth Programs Cost So Much — And How to Pay Less
May 2026 | BetterNewLives.com Price Research Team
A monthly semaglutide telehealth program costs $149–$299. A tirzepatide program costs $199–$499. The medication inside those programs costs roughly $40–$60 to produce and ship. This guide explains what happens to the rest of your money — and gives you concrete strategies to spend significantly less.
What the Medication Actually Costs
Compounded semaglutide and tirzepatide begin as bulk active pharmaceutical ingredient (API) synthesized primarily by chemical manufacturers in China and India. This API is purchased by licensed 503B outsourcing facilities or 503A compounding pharmacies, which then formulate it into injectable vials under controlled conditions.
The real production economics
Based on publicly available API pricing, wholesale reports, and compounding pharmacy cost structures, here is an approximate breakdown of what it costs to get a monthly supply of compounded semaglutide to your door:
| Cost Component | Estimated Cost | Notes |
|---|---|---|
| Semaglutide API (bulk) | $3–$8 | Per monthly dose equivalent, sourced at scale from API manufacturers |
| 503B compounding (labor, facilities, QC) | $12–$22 | Formulation, sterility testing, vial production, cGMP compliance overhead |
| Cold-chain packaging & shipping | $15–$25 | Insulated packaging, ice packs, overnight or 2-day shipping to patient |
| Supplies (syringes, swabs) | $4–$8 | Included in most programs |
| Total medication delivery cost | ~$34–$63 | What it costs to get the medication to you each month |
Against this ~$34–$63 medication delivery cost, a standard semaglutide program charges $149–$299/month. A tirzepatide program charges $199–$499/month. The difference goes to the telehealth platform's other operating costs — and profit.
Where the Rest of Your Money Goes
The markup is not pure profit. Telehealth platforms have real operating costs beyond medication. Here is how the economics break down:
Prescriber and clinical team
Every prescription requires a licensed medical provider — a physician, nurse practitioner, or physician assistant — who reviews your intake, issues the prescription, and is available for follow-up questions. At scale, telehealth platforms optimize this heavily through asynchronous messaging and brief video visits, but it still costs real money. Estimated per-patient monthly cost to the platform: $15–$35.
Platform technology and compliance
The software infrastructure for intake forms, electronic health records, prescription routing, patient messaging, lab integrations, and regulatory compliance is expensive to build and maintain. Telehealth platforms in this space are regulated as healthcare providers, adding compliance and legal overhead. Estimated per-patient monthly cost: $10–$25.
Customer support
GLP-1 patients have questions — about injection technique, side effects, dose schedules, prescription refills. High-quality programs staff clinical support teams. Lower-quality programs use chatbots and offshore support. Estimated per-patient monthly cost: $8–$20.
Customer acquisition — the biggest hidden cost
This is where the economics get striking. GLP-1 telehealth is one of the most competitive digital health markets in history. Hims & Hers, Ro Body, Noom, Found, and others are all bidding on the same Google, Meta, and TikTok keywords. Customer acquisition costs (CAC) in this market are estimated at $150–$400 per new patient. That cost has to be recovered over the customer's lifetime on the platform — which means early months are often loss-leaders even at $299/month.
The profit that remains
After all operating costs, well-run telehealth platforms at scale likely operate at gross margins of 40–60% on medication programs — and higher on patients who stay long-term. For a patient paying $297/month and staying for 12 months, total revenue is $3,564. At a 50% margin, that's roughly $1,782 in contribution margin per patient per year. For platforms with hundreds of thousands of patients, this is a very large business.
The Brand-Name Loophole Most People Miss
Here is the most under-utilized cost-saving option for GLP-1 medications: Eli Lilly's savings card programs for Mounjaro and Zepbound.
How the savings cards work
Eli Lilly offers manufacturer savings cards for both Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss). For eligible commercially insured patients — meaning you have private insurance, but your plan does not fully cover the drug — these cards can reduce your out-of-pocket cost to as little as $25 per month. Without the card, the same prescription costs $900–$1,200/month.
Novo Nordisk offers similar savings programs for Ozempic and Wegovy (semaglutide). These programs change periodically, so verify current terms directly with the manufacturer or your pharmacy at the time of your prescription.
Who qualifies — and who doesn't
| Situation | Savings Card? | Notes |
|---|---|---|
| Commercial insurance, drug not covered | Usually eligible | Best case — card can bring cost to $25/mo |
| Commercial insurance, drug partially covered | Often eligible | Card covers copay gap — check terms |
| No insurance (uninsured) | Card only | Savings card may still apply; also check patient assistance programs |
| Medicare / Medicaid | Not eligible | Federal law prohibits manufacturer coupons for government insurance |
| Employer self-funded plan | Varies | Some self-funded plans opt out — check with your HR or insurer |
6 Ways to Pay Less for Your GLP-1 Program
When a Telehealth Program IS Worth the Price
Despite the high margins, telehealth GLP-1 programs do provide genuine value in some situations. The cost is most justified when:
- You have no insurance and don't qualify for savings cards. At full brand-name list price, a $199–$299/month compounded program saves $600–$900/month versus Ozempic or Mounjaro.
- You want medical oversight but can't see a specialist quickly. Telehealth makes prescriber access fast and convenient. For someone who would otherwise wait months to see an endocrinologist, the bundled prescription access has real value.
- You benefit from the accountability structure. Regular check-ins, clinical messaging, and built-in dose adjustment support help some patients stay on track in ways that a bare prescription alone doesn't.
- You're on a program that actually includes everything. A $297/month flat-rate program that covers Rx, medication at any dose, supplies, and ongoing clinical support is a different value proposition than a $149/month entry offer that charges separately for higher doses, supplies, and consultations. Read the terms carefully.
Where Prices Are Heading
The GLP-1 telehealth market is young, competitive, and still sorting out its long-run pricing structure. Several forces are pushing prices lower:
Increasing API supply and compounding competition
As more API manufacturers and 503B compounding facilities have entered the market, the cost to produce compounded semaglutide and tirzepatide has declined. These savings have been passed on to consumers partially, with program prices falling modestly since their peaks in 2023–2024. This trend is likely to continue.
Growing telehealth competition
The number of telehealth platforms offering GLP-1 programs has multiplied. As the market matures, margin compression tends to follow. Programs that can't differentiate on quality will be forced to compete more aggressively on price.
The compounding regulatory wildcard
The FDA has been updating its position on compounded GLP-1 medications as the official shortage list status evolves. If compounding restrictions tighten significantly, it would reduce supply and potentially push prices back up for compounded programs — while benefiting brand-name manufacturers. This regulatory uncertainty is a meaningful risk for anyone planning a long-term compounded program.
Biosimilar and generic timeline
Semaglutide's patents don't expire until the late 2020s to early 2030s depending on jurisdiction and formulation. Tirzepatide's timeline is similar. True generic competition for the brand-name products is years away. Until then, the pricing power of Novo Nordisk and Eli Lilly in the prescription market remains intact — which continues to support telehealth program pricing well above the underlying medication cost.
Compare Programs Before You Enroll
See side-by-side pricing for all major telehealth programs — entry price, standard price, what's included, and how to evaluate them.
Semaglutide Programs → Tirzepatide Programs →